CASC3 and plasma cell myeloma: Drugs from this group reduce the expression of FOXM1, thus limiting the proliferation of neoplastic cells [43], but its increased expression was observed in myeloma cells in relapsed patients, which may indicate the involvement of this gene in the development of resistance to BTZ [44].